Charles River Beats Q1 Estimates on Drug Development Demand

CHARLES RIVER LABORATORIES beat first-quarter profit estimates with adjusted earnings of $2.06 per share on steady drug development demand. The result surpassed the $1.94 per share average analyst estimate for the period ended March 28. This performance signals a recovery for contract research organizations as pharmaceutical clients resume spending on discovery and safety testing.

### Discovery Services Drive Revenue Growth Quarterly revenue reached $995.8 million, exceeding the $977.5 million projected by analysts according to LSEG data. The discovery and safety assessment segment led the performance, with revenue rising 0.7% to $596.9 million. Charles River maintained its full-year adjusted profit forecast between $10.80 and $11.30 per share.